NASDAQ:ILMN

Illumina Stock Forecast, Price & News

$455.35
+9.94 (+2.23 %)
(As of 06/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$442.23
$457.57
50-Day Range
$372.84
$455.35
52-Week Range
$260.42
$555.77
Volume527,414 shs
Average Volume1.05 million shs
Market Capitalization$66.48 billion
P/E Ratio106.39
Dividend YieldN/A
Beta0.94
30 days | 90 days | 365 days | Advanced Chart
Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.


Illumina logo

About Illumina

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.19 out of 5 stars

Medical Sector

972nd out of 2,100 stocks

Analytical Instruments Industry

19th out of 32 stocks

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Illumina (NASDAQ:ILMN) Frequently Asked Questions

Is Illumina a buy right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 4 sell ratings, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View analyst ratings for Illumina
or view top-rated stocks.

What stocks does MarketBeat like better than Illumina?

Wall Street analysts have given Illumina a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Illumina wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Illumina
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings data on Tuesday, April, 27th. The life sciences company reported $1.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.53. The life sciences company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a net margin of 18.14% and a trailing twelve-month return on equity of 14.81%. During the same quarter in the previous year, the company posted $1.64 EPS.
View Illumina's earnings history
.

How has Illumina's stock been impacted by COVID-19?

Illumina's stock was trading at $246.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ILMN stock has increased by 85.1% and is now trading at $455.35.
View which stocks have been most impacted by COVID-19
.

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its first quarter 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $1.09 billion-$1.09 billion, compared to the consensus revenue estimate of $924.60 million.

What price target have analysts set for ILMN?

17 analysts have issued 12 month target prices for Illumina's shares. Their forecasts range from $280.00 to $570.00. On average, they anticipate Illumina's share price to reach $374.50 in the next twelve months. This suggests that the stock has a possible downside of 17.8%.
View analysts' price targets for Illumina
or view top-rated stocks among Wall Street analysts.

Who are Illumina's key executives?

Illumina's management team includes the following people:
  • Mr. Francis A. deSouza, CEO & Director (Age 50) (LinkedIn Profile)
  • Mr. Sam A. Samad, Chief Financial Officer (Age 51, Pay $716.04k) (LinkedIn Profile)
  • Dr. Alexander Aravanis M.D., Ph.D., CTO & Head of Research and Product Devel. (Age 45, Pay $416.48k) (LinkedIn Profile)
  • Ms. Susan H. Tousi, Chief Commercial Officer (Age 52, Pay $655.31k) (LinkedIn Profile)
  • Stephanie Campos, Pres
  • Mr. Robert P. Ragusa, Chief Operations Officer (Age 61) (LinkedIn Profile)
  • Mr. Jose A. Torres Jr., Chief Accounting Officer & VP (Age 46)
  • Mr. Steve Phillpott, Sr. VP & Chief Information Officer
  • Mr. Charles E. Dadswell, Sr. VP, Gen. Counsel & Sec. (Age 62) (LinkedIn Profile)
  • Mr. Eric Endicott, Sr. Director of Corp. Communications

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among Illumina's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Illumina's key competitors?

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), The Walt Disney (DIS), PayPal (PYPL), salesforce.com (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (14.68%), Edgewood Management LLC (4.28%), Loomis Sayles & Co. L P (2.30%), Sands Capital Management LLC (1.97%), Janus Henderson Group PLC (1.87%) and Geode Capital Management LLC (1.65%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina
.

Which major investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Russell Investments Group Ltd., Edgewood Management LLC, Generation Investment Management LLP, Ameriprise Financial Inc., Sustainable Growth Advisers LP, Korea Investment CORP, and Alliancebernstein L.P.. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Phillip G Febbo, and Susan H Tousi.
View insider buying and selling activity for Illumina
or view top insider-selling stocks.

Which major investors are buying Illumina stock?

ILMN stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Ownership Capital B.V., Veritas Asset Management LLP, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, RTW Investments LP, GSB Wealth Management LLC, and Riverbridge Partners LLC.
View insider buying and selling activity for Illumina
or or view top insider-buying stocks.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $455.35.

How much money does Illumina make?

Illumina has a market capitalization of $66.48 billion and generates $3.24 billion in revenue each year. The life sciences company earns $656 million in net income (profit) each year or $4.50 on an earnings per share basis.

How many employees does Illumina have?

Illumina employs 7,850 workers across the globe.

Does Illumina have any subsidiaries?

The following companies are subsidiares of Illumina: Advanced Liquid Logic, Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Edico Genome Corp., Enancio, Epicentre Biotechnologies, Epicentre Technologies Corporation, FC Ops Corp., GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada Inc., Illumina Denmark ApS, Illumina Finland Oy, Illumina France Holding Sarl, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina Iceland ehf, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus, Illumina Shanghai (Trading) Co Ltd, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.

When was Illumina founded?

Illumina was founded in 1998.

What is Illumina's official website?

The official website for Illumina is www.illumina.com.

Where are Illumina's headquarters?

Illumina is headquartered at 200 ILLUMINA WAY, SAN DIEGO CA, 92122.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]


This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.